Verge Genomics Secures $98 Million in New Financing
Retrieved on:
星期四, 十二月 16, 2021
Biotechnology, Health, Pharmaceutical, Other Technology, Technology, Tao, Lilly, BlackRock, Series, Company, Genomics, ALS, Eli Lilly and Company, Venture round, LLC, Health, Drug discovery, CEO, Machine learning, Vulcan Inc., Artificial intelligence, Patient, Drug development, Neuroscience, Section 32, Verge, Efficiency, Investment, Program, GHI, Digital health, Amyotrophic lateral sclerosis, Partnership, Digital, Technology, Pharmaceutical industry, Medical device, Merck, Verge Genomics, Merck Global Health Innovation Fund, VERGE GENOMICS, MERCK GLOBAL HEALTH INNOVATION FUND
Verge Genomics, a tech-enabled drug discovery company pioneering the use of artificial intelligence (AI) and human data to develop new drugs, announced today it has closed an oversubscribed $98 million equity financing.
Key Points:
- Verge Genomics, a tech-enabled drug discovery company pioneering the use of artificial intelligence (AI) and human data to develop new drugs, announced today it has closed an oversubscribed $98 million equity financing.
- Verge has built an end-to-end, AI-driven drug discovery platform that includes one of the fields largest proprietary genomic datasets from human brain tissue.
- Verge has built an end-to-end drug discovery and development platform, featuring one of the fields largest and most comprehensive proprietary patient genomics datasets in neuroscience.
- www.merckghifund.com
Shumaker, Loop & Kendrick LLP and Green Shoots Consulting, LLC acted as advisors to Merck GHI in connection with the Verge Genomics transaction.